Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
about
Loxapine inhaler for psychosis-induced aggression or agitationAutomatic filtering and substantiation of drug safety signalsOff-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.The comparative efficacy of intramuscular antipsychotics for the management of acute agitation.A new clinical guideline to improve sedation safety in patients transferred under the Mental Health Act from remote parts of Western Australia.The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies.Cardiovascular risk assessment of atypical antipsychotic drugs in a zebrafish model.
P2860
Q24197864-C8B6354E-B46F-4DB9-B045-6BE2FF5A4A41Q28482131-A5C2140D-0B2C-4688-B5F2-A0B05CBFE08AQ37248061-41CCF0C0-0BAA-4785-9D28-1F2CA7DE5BB3Q38133452-456D849E-2CAF-49F4-8645-DE7697E029EDQ38242166-C6073386-556A-4A13-A1B6-986E7CD36E0CQ45948688-19C75FEB-6867-431A-9F32-BD928090BE31Q46591770-7D62D083-A5FD-4CBD-A289-5FDD8E04D24F
P2860
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
description
im Jahr 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2006
@uk
name
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@en
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@nl
type
label
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@en
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@nl
prefLabel
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@en
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@nl
P356
P1476
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
@en
P2093
Nasser Abdelmawla
P356
10.1192/APT.12.1.35
P577
2006-01-01T00:00:00Z